Pfizer, BioNTech seek to revoke CureVac's patent infringement claims (updated)

CureVac NV

02/09/2022 15:05

(Adds background on lawsuits)
    Sept 2 (Reuters) - Pfizer  PFE.N  and its German partner
BioNTech  BNTX.O  have filed proceedings at the High Court of
England and Wales,  seeking a judgment that their COVID-19
vaccine, based on mRNA technology, does not infringe on
CureVac's  CVAC.O  European patents, according to a regulatory
filing on Friday.
    In July, CureVac had filed a patent lawsuit against BioNTech
over its use of mRNA technology, seeking fair compensation from
the company and two subsidiaries for infringement of its
intellectual properly rights.
    Pfizer and BioNTech later filed a complaint with a U.S.
district court, seeking a judgment that they did not infringe
U.S. patents held by CureVac.
    Pfizer and BioNTech are also facing patent infringement
lawsuits from other companies.  urn:newsml:reuters.com:*:nL4N3022O2
    Last month, rival mRNA vaccine maker Moderna  MRNA.O  filed
a patent lawsuit against the companies related to their COVID-19
shot.  urn:newsml:reuters.com:*:nL1N3020TW

 (Reporting by Amruta Khandekar; Editing by Maju Samuel)
 ((Amruta.Khandekar@thomsonreuters.com;))